Cytotoxic T‐Lymphocyte Clones, Established by Stimulation with the HLA‐A2 Binding p5365–73 Wild Type Peptide Loaded on Dendritic Cells In Vitro, Specifically Recognize and Lyse HLA‐A2 Tumour Cells Overexpressing the p53 Protein

• Published in: Scandinavian journal of immunology Vol. 51; no. 2; pp. 128 - 133
• Main Authors: Barfoed, A M, Petersen, T R, Kirkin, A F, Thor Straten, P, Claesson, M H, Zeuthen, J
• Format: Journal Article
• Language: English
• Published: Oxford, U.K. and Cambridge, USA Blackwell Science Ltd 01.02.2000
• Subjects: Cell Line, Transformed; Cells, Cultured; Clone Cells; Coculture Techniques; Cytotoxicity, Immunologic - immunology; Dendritic Cells - immunology; Gene Expression; HLA-A2 Antigen - immunology; Humans; K562 Cells; Male; Mutation; Peptides - immunology; Peptides - metabolism; Receptors, Antigen, T-Cell - genetics; T-Lymphocytes, Cytotoxic - cytology; T-Lymphocytes, Cytotoxic - immunology; Tumor Cells, Cultured; Tumor Suppressor Protein p53 - biosynthesis; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - immunology
• ISSN: 0300-9475; 1365-3083
• DOI: 10.1046/j.1365-3083.2000.00668.x

Mutations in the tumour suppressor gene p53 are among the most frequent genetic alterations in human malignancies, often associated with an accumulation of the p53 protein in the cytoplasm. We have generated a number of cytotoxic T lymphocyte (CTL) clones that specifically recognize the HLA‐A*0201 p53 wild type peptide RMPEAAPPV [65–73], designated R9V, by the in vitro stimulation of CD8 enriched peripheral blood lymphocytes from a healthy HLA‐A*0201 donor using peptide loaded autologous dendritic cells. A total of 22 CTL clones were generated from the same bulk culture and demonstrated to carry identical T‐cell receptors. The CTL clone, 2D9, was shown to specifically lyse the HLA‐A*0201+ squamous carcinoma cell line SCC9 and the breast cancer cell line MDA‐MB‐468. Our data demonstrate that human peripheral blood lymphocytes from normal healthy individuals comprise T cells capable of recognizing p53 derived wild type (self) peptides. Furthermore, the capacity of R9V specific T cell clones to exert HLA restricted cytotoxicity, argues that the R9V peptide is naturally presented on certain cancer cells. This supports the view that p53 derived wild type peptides might serve as candidate target antigens for the immunotherapeutic treatment of cancer.